Figure 4. Time course of the TP53 mutant allele burden in serial follow-up samples of lower-risk MDS.

The frequency of TP53 mutations during follow-up of individual patients stratified by the mutational burden and the time of mutation acquisition. (A) The first group of patients with VAF > 6% at the time of diagnosis; (B) the second group with VAF < 6% at the time of diagnosis; (C) the third group of patients who acquired a mutation in the course of the disease. Abbreviations: LEN, lenalidomide treatment; AZA, 5-azacytidine treatment; IT, induction therapy; HSCT, hematopoietic stem cell transplantation; *, examinations performed from peripheral blood; %, % of variant allele frequency.